WO2006033854A3 - Aptamers to von willebrand factor and their use as thrombotic disease therapeutics - Google Patents

Aptamers to von willebrand factor and their use as thrombotic disease therapeutics Download PDF

Info

Publication number
WO2006033854A3
WO2006033854A3 PCT/US2005/032134 US2005032134W WO2006033854A3 WO 2006033854 A3 WO2006033854 A3 WO 2006033854A3 US 2005032134 W US2005032134 W US 2005032134W WO 2006033854 A3 WO2006033854 A3 WO 2006033854A3
Authority
WO
WIPO (PCT)
Prior art keywords
von willebrand
willebrand factor
aptamers
thrombotic disease
disease therapeutics
Prior art date
Application number
PCT/US2005/032134
Other languages
French (fr)
Other versions
WO2006033854A2 (en
Inventor
John L Diener
Daniel H A Lagasse
Original Assignee
Archemix Corp
John L Diener
Daniel H A Lagasse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp, John L Diener, Daniel H A Lagasse filed Critical Archemix Corp
Priority to AU2005287273A priority Critical patent/AU2005287273B2/en
Priority to BRPI0514984-3A priority patent/BRPI0514984A/en
Priority to JP2007530504A priority patent/JP2008512098A/en
Priority to EP05812108A priority patent/EP1789096A4/en
Priority to MX2007002772A priority patent/MX2007002772A/en
Priority to CA002579374A priority patent/CA2579374A1/en
Publication of WO2006033854A2 publication Critical patent/WO2006033854A2/en
Priority to IL181689A priority patent/IL181689A0/en
Publication of WO2006033854A3 publication Critical patent/WO2006033854A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl

Abstract

The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnositcs of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.
PCT/US2005/032134 2004-09-07 2005-09-07 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics WO2006033854A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005287273A AU2005287273B2 (en) 2004-09-07 2005-09-07 Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
BRPI0514984-3A BRPI0514984A (en) 2004-09-07 2005-09-07 aptamers for von willebrand factor and their use as therapeutics for thrombotic disease
JP2007530504A JP2008512098A (en) 2004-09-07 2005-09-07 Aptamers against von Willebrand factor and their use as treatments for thrombotic diseases
EP05812108A EP1789096A4 (en) 2004-09-07 2005-09-07 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
MX2007002772A MX2007002772A (en) 2004-09-07 2005-09-07 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics.
CA002579374A CA2579374A1 (en) 2004-09-07 2005-09-07 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
IL181689A IL181689A0 (en) 2004-09-07 2007-03-04 Aptamers to von willebrand factor and pharmaceutical compositions containing the same

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US60804704P 2004-09-07 2004-09-07
US60/608,047 2004-09-07
US66195005P 2005-03-11 2005-03-11
US60/661,950 2005-03-11
US67842705P 2005-05-06 2005-05-06
US60/678,427 2005-05-06
US69023105P 2005-06-13 2005-06-13
US60/690,231 2005-06-13

Publications (2)

Publication Number Publication Date
WO2006033854A2 WO2006033854A2 (en) 2006-03-30
WO2006033854A3 true WO2006033854A3 (en) 2007-05-31

Family

ID=36090463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032134 WO2006033854A2 (en) 2004-09-07 2005-09-07 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics

Country Status (11)

Country Link
US (1) US7998940B2 (en)
EP (1) EP1789096A4 (en)
JP (1) JP2008512098A (en)
KR (1) KR20070101227A (en)
AU (1) AU2005287273B2 (en)
BR (1) BRPI0514984A (en)
CA (1) CA2579374A1 (en)
IL (1) IL181689A0 (en)
MX (1) MX2007002772A (en)
SG (1) SG156618A1 (en)
WO (1) WO2006033854A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859518B2 (en) 2004-04-22 2014-10-14 Regado Biosciences, Inc. Modulators of coagulation factors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2351855A1 (en) 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
MX2007016561A (en) * 2005-06-30 2008-03-10 Archemix Corp Materials and methods for the generation of fully 2'-modified nucleic acid transcripts.
EP2207891B1 (en) * 2006-12-22 2012-07-25 Archemix LLC Materials and methods for the generation of transcripts comprising modified nucleotides
JP5349323B2 (en) * 2007-01-10 2013-11-20 アーケミックス コーポレイション Materials and methods for generating transcripts containing modified nucleotides
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
RU2571660C2 (en) * 2009-06-03 2015-12-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Modifiers of glycoprotein vi representing nucleic acid
JP2011024499A (en) * 2009-07-27 2011-02-10 Nec Soft Ltd Method for producing nucleic acid, tag nucleic acid for delivery which can organ-specifically deliver delivery object, and use thereof
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
JP5337096B2 (en) * 2010-04-28 2013-11-06 株式会社日立製作所 Evaluation of arteriosclerosis
US20110306653A1 (en) 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
KR101250557B1 (en) * 2011-05-18 2013-04-03 국립암센터 PAUF-specific aptamer and therapeutic composition for treatment of pancreatic cancer comprising thereof
US20140234217A1 (en) 2011-09-30 2014-08-21 Mallinckrodt Llc Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
SG11201606379UA (en) * 2014-02-05 2016-09-29 Univ Deakin Aptamer construct
AU2016218945B2 (en) 2015-02-11 2021-08-26 Deakin University EpCAM aptamers and conjugates thereof
WO2016143700A1 (en) * 2015-03-06 2016-09-15 タグシクス・バイオ株式会社 Method for stabilizing dna aptamer
CA3003576A1 (en) * 2015-10-30 2017-05-04 Tagcyx Biotechnologies Dna aptamer that binds to vwf
JP2019528739A (en) * 2016-09-16 2019-10-17 デューク ユニバーシティ Von Willebrand factor (VWF) targeted drug and method using the same
EP3624801A4 (en) * 2017-05-19 2021-02-24 Band Therapeutics, LLC Compositions and methods for the treatment of complications and disorders relating to von willebrand factor
WO2021019301A2 (en) * 2019-07-26 2021-02-04 Aratinga.Bio Aci Anti-cd3 aptamers for use in cell targeting and labeling
US20230038761A1 (en) * 2020-02-04 2023-02-09 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
FR2548562B1 (en) * 1983-07-08 1989-02-24 Commissariat Energie Atomique COMPOSITE LOPIN FOR HOT PROCESSING
US4959309A (en) * 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE229046T1 (en) 1985-03-30 1987-12-17 Marc Genf/Geneve Ch Ballivet METHOD FOR OBTAINING DNA, RNS, PEPTIDES, POLYPEPTIDES OR PROTEINS BY DNA RECOMBINANT METHOD.
NL8500961A (en) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic CDNA CODING FOR THE HUMANE VON WILLEBRAND FACTOR, PLASMIDS WITH SUCH CDNA CODING, RESPECTIVE FRAGMENTS, AND MICRO-ORGANISMS CONTAINING SUCH PLASMS.
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5900476A (en) 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
FR2619314B1 (en) * 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US5340727A (en) * 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
EP1201757A3 (en) 1988-12-22 2002-09-11 Genentech, Inc. Method for preparing water soluble polypeptides
DE3904354A1 (en) 1989-02-14 1990-08-16 Behringwerke Ag PASTEURIZED, PURIFIED OF WILLEBRAND FACTOR CONCENTRATE AND METHOD FOR THE PRODUCTION THEREOF
US5686569A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5318899A (en) 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
US5849536A (en) 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US6008193A (en) 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5635615A (en) 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5648214A (en) 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5763173A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5459015A (en) 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
EP1493825A3 (en) * 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
EP0552178B1 (en) 1990-10-12 1997-01-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
ES2109336T3 (en) * 1990-11-26 1998-01-16 Genetics Inst EXPRESSION OF PACE IN HOST CELLS AND METHODS OF USING IT.
IE920562A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5321127A (en) * 1991-03-18 1994-06-14 Brigham And Women's Hospital Antiplatelet and antithrombotic activity of platelet glycoprotein Ib receptor fragments
ATE283864T1 (en) 1991-06-20 2004-12-15 Aventis Behring L L C A METHOD FOR PRODUCING THERAPEUTICALLY EFFECTIVE FRAGMENTS OF VON WILLEBRAND FACTOR
US5847086A (en) 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
FR2680518A1 (en) 1991-08-21 1993-02-26 Rhone Poulenc Rorer Sa YEAST PROMOTER AND USE THEREOF
US5298239A (en) * 1991-10-07 1994-03-29 The Research Foundation Of State University Of New York Mutations rendering platelet glycoprotein IB α less reactive
US5317097A (en) 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US6114135A (en) 1991-11-08 2000-09-05 Goldstein; Sheldon Multiple coagulation test system and method of using a multiple coagulation test system
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
US5336667A (en) * 1991-12-03 1994-08-09 Temple University Of The Commonwealth System Of Higher Education Method for inhibiting the ahesion of platelet with alboaggregins: platelet agonists which bind to platelet membrane glycoprotein IB
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5180853A (en) * 1992-05-04 1993-01-19 Dave Paritosh R 4,4-6,6-tetronitroadamantan-2-one
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DK0623615T3 (en) 1993-05-01 1999-12-13 Merck Patent Gmbh Adhesion receptor antagonists
UA41332C2 (en) 1993-07-01 2001-09-17 Мерк Патент Гмбх Protein inhibiting collagen-stimulated activation and aggregation of thrombocytes, method for its isolation, pharmaceutical composition, method for treating implanted or extracorporeal devices, method for producing medicinal agent
US5817635A (en) 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5856126A (en) 1993-09-22 1999-01-05 Ajinomoto Co., Inc. Peptide having anti-thrombus activity and method of producing the same
DE4332384A1 (en) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhesion receptor antagonists III
US5869615A (en) 1994-01-03 1999-02-09 Washington University Modified complement proteases
WO1995021853A1 (en) * 1994-02-10 1995-08-17 Nexstar Pharmaceuticals, Inc. High-affinity ligands of basic fibroblast growth factor and thrombin
DE4405378A1 (en) 1994-02-19 1995-08-24 Merck Patent Gmbh Adhesion receptor antagonists
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5462752A (en) * 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
US5880327A (en) 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US5763199A (en) 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
DE4435485C1 (en) 1994-10-04 1996-03-21 Immuno Ag Process for obtaining high-purity von Willebrand factor
US5916805A (en) 1994-11-30 1999-06-29 Ajinomoto Co., Inc. Antithrombotic agent and anti-von Willebrand factor monoclonal antibody
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
DE69638318D1 (en) 1995-06-07 2011-02-17 Gilead Sciences Inc Nucleic acid ligands that bind to and inhibit DNA polymerases
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
AT404838B (en) 1995-11-24 1999-03-25 Immuno Ag PRODUCTION OF PROTEINS FROM PRO-PROTEINS BY FUSION PROTEINS DERIVED FROM FURIN OR FURINANALOGS
USRE38431E1 (en) 1995-12-01 2004-02-17 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
JP3735921B2 (en) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 GPIb / lipid complex and uses thereof
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
US5811151A (en) 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US6074832A (en) 1996-07-19 2000-06-13 The Regents Of The University Of Michigan DNA encoding canine von Willebrand factor and methods of use
US6040143A (en) 1996-07-19 2000-03-21 The Regents Of The University Of Michigan DNA encoding von Willebrand factor and methods of use
US6780583B1 (en) 1996-07-19 2004-08-24 Board Of Trustees Operating Michigan State University DNA encoding canine von willebrand factor and methods of use
DE19639103A1 (en) 1996-09-24 1998-03-26 Hoechst Ag DNA construct with inhibitory mutation and corrective mutation
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
AT406867B (en) 1997-02-27 2000-10-25 Immuno Ag METHOD FOR OBTAINING HIGH PURITY VWF OR FACTOR VIII / VWF COMPLEX
AT405403B (en) 1997-02-27 1999-08-25 Immuno Ag CLEANING OF WILLEBRAND FACTOR BY CATION EXCHANGER CHROMATOGRAPHY
DE19710643A1 (en) 1997-03-14 1998-09-17 Hoechst Ag The promoter of the cdc25B gene and its use in gene therapy
GB9705787D0 (en) 1997-03-20 1997-05-07 Thrombosis Res Inst Modified dendroaspins
WO1998042753A1 (en) 1997-03-27 1998-10-01 Trustees Of Boston University Novel antiplatelet agent
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (en) 1997-06-20 2001-02-26 Immuno Ag RECOMBINANT CELL CLONE WITH INCREASED STABILITY IN SERUM- AND PROTEIN-FREE MEDIUM AND METHOD FOR OBTAINING THE STABLE CELL CLONE
US6410237B1 (en) 1997-07-18 2002-06-25 Board Of Trustees Operating Michigan State University DNA encoding canine von Willebrand factor and methods of use
US6656731B1 (en) 1997-09-22 2003-12-02 Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid catalysts with endonuclease activity
EP1030934A4 (en) 1997-11-10 2004-03-17 Univ California Biochemical methods for detecting cervical dysplasia and cancer
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
DE10022092A1 (en) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilized protein preparation and process for its preparation
US20050136056A1 (en) 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004047742A2 (en) 2002-11-21 2004-06-10 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US20050037394A1 (en) 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
CA2506748A1 (en) 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2'-substituted nucleic acids
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HWANG S. ET AL.: "Inhibition of gene expression in human cells through small molecule-RNA interactions", PROC. NATL. ACAD. SCI., vol. 96, no. 23, 9 November 1999 (1999-11-09), pages 12997 - 13002, XP002270781 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859518B2 (en) 2004-04-22 2014-10-14 Regado Biosciences, Inc. Modulators of coagulation factors

Also Published As

Publication number Publication date
US20090149643A1 (en) 2009-06-11
KR20070101227A (en) 2007-10-16
IL181689A0 (en) 2007-07-04
WO2006033854A2 (en) 2006-03-30
CA2579374A1 (en) 2006-03-30
MX2007002772A (en) 2008-03-05
JP2008512098A (en) 2008-04-24
AU2005287273B2 (en) 2011-05-12
US7998940B2 (en) 2011-08-16
EP1789096A2 (en) 2007-05-30
EP1789096A4 (en) 2009-07-08
AU2005287273A1 (en) 2006-03-30
SG156618A1 (en) 2009-11-26
BRPI0514984A (en) 2008-07-01

Similar Documents

Publication Publication Date Title
WO2006033854A3 (en) Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
WO2007025049A3 (en) Aptamers that bind thrombin with high affinity
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2007044534A3 (en) Vegf analogs and methods of use
TW200740849A (en) Dual variable domain immunoglobulin and uses thereof
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
CA2818990C (en) Designed repeat proteins binding to serum albumin
HK1185895A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r il-22 il-22r
WO2008116149A3 (en) Apoptotic anti- ige antibodies binding the membrane-bound ige
WO2008024188A8 (en) Dual variable domain immunoglobulin and uses thereof
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
UA105290C2 (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
EP2467167A4 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
EA200600735A1 (en) NUCLEIC ACIDS, SPECIFICALLY BINDING BIOACTIVE GREELINE
EP4180816A3 (en) Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates
WO2003057856A3 (en) Dominant negative proteins and methods thereof
WO2006096222A3 (en) Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
WO2008134445A8 (en) Platelet activation receptor clec-2: compositions and uses thereof
WO2005077397A3 (en) Methods and compositions for treating vascular diseases
WO2007012748A3 (en) Novel milk protein fractions and use thereof for preventing or treating chronic inflammatory diseases
WO2005052121A3 (en) Multivalent aptamers
WO2010091396A3 (en) Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
EP2500356A3 (en) Dual variable domain immunoglobulin and uses thereof
WO2005113813A3 (en) Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580035683.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181689

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2579374

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007530504

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002772

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005287273

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 553899

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007/02520

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005287273

Country of ref document: AU

Date of ref document: 20050907

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287273

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005812108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1217/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077007994

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007112945

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005812108

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514984

Country of ref document: BR